S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Laser breakthrough could send stock soaring 2,467% (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Laser breakthrough could send stock soaring 2,467% (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Laser breakthrough could send stock soaring 2,467% (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Laser breakthrough could send stock soaring 2,467% (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home

Kymera Therapeutics (KYMR) SEC Filings & 10K Form

$13.90
-0.40 (-2.80%)
(As of 09/29/2023 ET)
Compare
Today's Range
$13.85
$14.54
50-Day Range
$13.90
$23.88
52-Week Range
$13.85
$39.85
Volume
754,422 shs
Average Volume
413,206 shs
Market Capitalization
$770.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$48.10

Recent Kymera Therapeutics SEC Filings

DateFilerForm TypeView
08/03/2023
6:10 AM
Kymera Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/03/2023
6:16 AM
Kymera Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
06/20/2023
4:55 PM
BIOTECHNOLOGY VALUE FUND II LP (Reporting)
BIOTECHNOLOGY VALUE FUND L P (Reporting)
Biotechnology Value Trading Fund OS LP (Reporting)
BVF GP HOLDINGS LLC (Reporting)
BVF I GP LLC (Reporting)
BVF II GP LLC (Reporting)
BVF INC/IL (Reporting)
BVF PARTNERS L P/IL (Reporting)
BVF Partners OS Ltd. (Reporting)
Kymera Therapeutics (Issuer)
LAMPERT MARK N (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/20/2023
3:15 PM
Hrustanovic Gorjan (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/20/2023
3:15 PM
Esposito Pamela (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/20/2023
3:15 PM
Albers Jeffrey W. (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/20/2023
3:15 PM
Horobin Joanna (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/20/2023
3:15 PM
Booth Bruce (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/20/2023
3:15 PM
Kymera Therapeutics (Issuer)
Ridloff Elena (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/20/2023
3:15 PM
Kymera Therapeutics (Issuer)
MARAGANORE JOHN (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/20/2023
3:15 PM
Kymera Therapeutics (Issuer)
Morgan Leigh (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/20/2023
3:16 PM
Kymera Therapeutics (Issuer)
Sandor Victor (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/02/2023
1:17 PM
Jacobs Bruce N. (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/22/2023
6:28 PM
Chadwick Jeremy G (Reporting)
Kymera Therapeutics (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
05/22/2023
6:35 PM
Chadwick Jeremy G (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/22/2023
3:45 PM
Kymera Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/04/2023
6:10 AM
Kymera Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/04/2023
6:16 AM
Kymera Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
03/10/2023
4:30 PM
Kymera Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/03/2023
3:30 PM
Jacobs Bruce N. (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2023
3:30 PM
Gollob Jared (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2023
3:31 PM
Kymera Therapeutics (Issuer)
Mainolfi Nello (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/27/2023
4:22 PM
Kymera Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/23/2023
6:31 AM
Kymera Therapeutics (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
02/23/2023
6:11 AM
Kymera Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/23/2023
6:16 AM
Kymera Therapeutics (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/14/2023
3:28 PM
Atlas Venture Fund X, L.P. (Filed by)
Kymera Therapeutics (Subject)
Form SC 13G/A
02/14/2023
8:37 AM
Avoro Capital Advisors LLC (Filed by)
Kymera Therapeutics (Subject)
Form SC 13G
02/08/2023
1:16 PM
Kymera Therapeutics (Subject)
STATE STREET CORP (Filed by)
Form SC 13G
02/06/2023
2:02 PM
Kymera Therapeutics (Subject)
WELLINGTON MANAGEMENT GROUP LLP (Filed by)
Form SC 13G/A
01/13/2023
4:08 PM
BIOTECHNOLOGY VALUE FUND II LP (Reporting)
BIOTECHNOLOGY VALUE FUND L P (Reporting)
Biotechnology Value Trading Fund OS LP (Reporting)
BVF GP HOLDINGS LLC (Reporting)
BVF I GP LLC (Reporting)
BVF II GP LLC (Reporting)
BVF INC/IL (Reporting)
BVF PARTNERS L P/IL (Reporting)
BVF Partners OS Ltd. (Reporting)
Kymera Therapeutics (Issuer)
LAMPERT MARK N (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/13/2023
3:50 PM
Atlas Venture Associates Opportunity I, L.P. (Reporting)
Atlas Venture Associates Opportunity I, LLC (Reporting)
ATLAS VENTURE ASSOCIATES X, L.P. (Reporting)
Atlas Venture Associates X, LLC (Reporting)
Atlas Venture Fund X, L.P. (Reporting)
Atlas Venture Opportunity Fund I, L.P. (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/13/2023
3:53 PM
Booth Bruce (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/10/2023
6:06 AM
Kymera Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/04/2023
3:35 PM
Chiniara Ellen (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/16/2022
4:03 PM
Atlas Venture Associates Opportunity I, L.P. (Reporting)
Atlas Venture Associates Opportunity I, LLC (Reporting)
ATLAS VENTURE ASSOCIATES X, L.P. (Reporting)
Atlas Venture Associates X, LLC (Reporting)
Atlas Venture Fund X, L.P. (Reporting)
Atlas Venture Opportunity Fund I, L.P. (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/16/2022
4:05 PM
Booth Bruce (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/14/2022
8:27 AM
Kymera Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/14/2022
6:16 AM
Kymera Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/08/2022
5:11 PM
Kymera Therapeutics (Issuer)
Mainolfi Nello (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/04/2022
3:30 PM
Atlas Venture Associates Opportunity I, L.P. (Reporting)
Atlas Venture Associates Opportunity I, LLC (Reporting)
ATLAS VENTURE ASSOCIATES X, L.P. (Reporting)
Atlas Venture Associates X, LLC (Reporting)
Atlas Venture Fund X, L.P. (Reporting)
Atlas Venture Opportunity Fund I, L.P. (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
11/04/2022
3:31 PM
Booth Bruce (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
11/03/2022
6:19 PM
Kymera Therapeutics (Issuer)
Sandor Victor (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
11/03/2022
6:22 PM
Kymera Therapeutics (Issuer)
Sandor Victor (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/03/2022
6:17 AM
Kymera Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/03/2022
6:20 AM
Kymera Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/01/2022
6:34 PM
Atlas Venture Associates Opportunity I, L.P. (Reporting)
Atlas Venture Associates Opportunity I, LLC (Reporting)
ATLAS VENTURE ASSOCIATES X, L.P. (Reporting)
Atlas Venture Associates X, LLC (Reporting)
Atlas Venture Fund X, L.P. (Reporting)
Atlas Venture Opportunity Fund I, L.P. (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
11/01/2022
6:36 PM
Booth Bruce (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/24/2022
7:00 AM
Jacobs Bruce N. (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/17/2022
7:09 PM
Kymera Therapeutics (Issuer)
Mainolfi Nello (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/17/2022
7:12 PM
Jacobs Bruce N. (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/13/2022
3:36 PM
Kymera Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)


Related Companies and Tools

This page (NASDAQ:KYMR) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -